Hazlehurst LA - Search Results

1

Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors.

Chen WC, Hu G, Hazlehurst LA. Chen WC, et al. Among authors: hazlehurst la. Curr Opin Pharmacol. 2020 Oct;54:36-43. doi: 10.1016/j.coph.2020.08.006. Epub 2020 Sep 6. Curr Opin Pharmacol. 2020. PMID: 32898723 Free PMC article. Review.

2

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.

Chen WC, Kanate AS, Craig M, Petros WP, Hazlehurst LA. Chen WC, et al. Among authors: hazlehurst la. Cancer Manag Res. 2017 Jul 12;9:307-314. doi: 10.2147/CMAR.S117477. eCollection 2017. Cancer Manag Res. 2017. PMID: 28744161 Free PMC article. Review.

3

Inhibition of the FAD containing ER oxidoreductin 1 (Ero1) protein by EN-460 as a strategy for treatment of multiple myeloma.

Hayes KE, Batsomboon P, Chen WC, Johnson BD, Becker A, Eschrich S, Yang Y, Robart AR, Dudley GB, Geldenhuys WJ, Hazlehurst LA. Hayes KE, et al. Among authors: hazlehurst la. Bioorg Med Chem. 2019 Apr 15;27(8):1479-1488. doi: 10.1016/j.bmc.2019.02.016. Epub 2019 Feb 10. Bioorg Med Chem. 2019. PMID: 30850265 Free PMC article.

4

Transient Receptor Potential C 1/4/5 Is a Determinant of MTI-101 Induced Calcium Influx and Cell Death in Multiple Myeloma.

Elzamzamy OM, Johnson BE, Chen WC, Hu G, Penner R, Hazlehurst LA. Elzamzamy OM, et al. Among authors: hazlehurst la. Cells. 2021 Jun 13;10(6):1490. doi: 10.3390/cells10061490. Cells. 2021. PMID: 34199280 Free PMC article.

5

Bone Marrow Stroma-Induced Transcriptome and Regulome Signatures of Multiple Myeloma.

Dziadowicz SA, Wang L, Akhter H, Aesoph D, Sharma T, Adjeroh DA, Hazlehurst LA, Hu G. Dziadowicz SA, et al. Among authors: hazlehurst la. Cancers (Basel). 2022 Feb 13;14(4):927. doi: 10.3390/cancers14040927. Cancers (Basel). 2022. PMID: 35205675 Free PMC article.

6

Emergence of Resistance to MTI-101 Selects for a MET Genotype and Phenotype in EGFR Driven PC-9 and PTEN Deleted H446 Lung Cancer Cell Lines.

Jones C, Dziadowicz S, Suite S, Eby A, Chen WC, Hu G, Hazlehurst LA. Jones C, et al. Among authors: hazlehurst la. Cancers (Basel). 2022 Jun 22;14(13):3062. doi: 10.3390/cancers14133062. Cancers (Basel). 2022. PMID: 35804837 Free PMC article.

7

Identification of Natural Product Sulfuretin Derivatives as Inhibitors for the Endoplasmic Reticulum Redox Protein ERO1α.

Johnson BD, Kaulagari S, Chen WC, Hayes K, Geldenhuys WJ, Hazlehurst LA. Johnson BD, et al. Among authors: hazlehurst la. ACS Bio Med Chem Au. 2022 Apr 20;2(2):161-170. doi: 10.1021/acsbiomedchemau.1c00062. Epub 2022 Jan 20. ACS Bio Med Chem Au. 2022. PMID: 35892127 Free PMC article.

8

Inflammatory Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma: Transcriptional Signature and In Vitro Modeling.

Wang L, Yi W, Ma L, Lecea E, Hazlehurst LA, Adjeroh DA, Hu G. Wang L, et al. Among authors: hazlehurst la. Cancers (Basel). 2023 Oct 26;15(21):5148. doi: 10.3390/cancers15215148. Cancers (Basel). 2023. PMID: 37958322 Free PMC article.

9

Molecular Signatures of CB-6644 Inhibition of the RUVBL1/2 Complex in Multiple Myeloma.

Yi W, Dziadowicz SA, Mangano RS, Wang L, McBee J, Frisch SM, Hazlehurst LA, Adjeroh DA, Hu G. Yi W, et al. Among authors: hazlehurst la. Int J Mol Sci. 2024 Aug 20;25(16):9022. doi: 10.3390/ijms25169022. Int J Mol Sci. 2024. PMID: 39201707 Free PMC article.

10

Targeting the bone marrow microenvironment in hematologic malignancies.

Dalton WS, Hazlehurst L, Shain K, Landowski T, Alsina M. Dalton WS, et al. Semin Hematol. 2004 Apr;41(2 Suppl 4):1-5. doi: 10.1053/j.seminhematol.2004.02.001. Semin Hematol. 2004. PMID: 15190509 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

74 results

Search Page

Filters